Showing results (1-10 of 10) with videos related to
Sort By:
Pageof 1
Expert Opinion on Therapeutic Targets|April 29, 2009
ADAM8: a new therapeutic target for asthmaMartin D Knolle, Caroline A OwenJournal of Immunology (Baltimore, Md. : 1950)|January 1, 2010
Matrix metalloproteinase-8 inactivates macrophage inflammatory protein-1 alpha to reduce acute lung inflammation and injury in micePablo A Quintero, Martin D Knolle, Luisa F Cala, et al.Journal of Immunology (Baltimore, Md. : 1950)|March 15, 2013
Profibrotic activities for matrix metalloproteinase-8 during bleomycin-mediated lung injuryVanessa J Craig, Pablo A Quintero, Susanne E Fyfe, et al.Frontiers in Immunology|October 26, 2018
MicroRNA-155 Protects Group 2 Innate Lymphoid Cells From Apoptosis to Promote Type-2 ImmunityMartin D Knolle, Shau Bing Chin, Batika M J Rana, et al.Thorax|June 19, 2021
Combining clinical, radiological and genetic approaches to pneumothorax managementHannah L Grimes, Simon Holden, Judith Babar, et al.Nature Immunology|December 22, 2022
An αvβ3 integrin checkpoint is critical for efficient TH2 cell cytokine polarization and potentiation of antigen-specific immunityAydan C H Szeto, Ana C F Ferreira, Jonathan Mannion, et al.Journal of Immunology (Baltimore, Md. : 1950)|May 15, 2013
Adam8 limits the development of allergic airway inflammation in miceMartin D Knolle, Takahiro Nakajima, Anja Hergrueter, et al.Science (New York, N.Y.)|June 27, 2024
Mef2d potentiates type-2 immune responses and allergic lung inflammationAydan C H Szeto, Paula A Clark, Ana C F Ferreira, et al.Immunity|June 17, 2018
Tissue-Restricted Adaptive Type 2 Immunity Is Orchestrated by Expression of the Costimulatory Molecule OX40L on Group 2 Innate Lymphoid CellsTimotheus Y F Halim, Batika M J Rana, Jennifer A Walker, et al.BMJ Open|October 6, 2020
How achievable are COVID-19 clinical trial recruitment targets? A UK observational cohort study and trials registry analysisNick G Cunniffe, Simon J Gunter, Michael Brown, et al.Pageof 1